{"protocolSection":{"identificationModule":{"nctId":"NCT03693300","orgStudyIdInfo":{"id":"D4194C00006"},"secondaryIdInfos":[{"id":"2018-002220-16","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","officialTitle":"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-04-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-13","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-21","type":"ACTUAL"},"studyFirstSubmitDate":"2018-09-11","studyFirstSubmitQcDate":"2018-10-01","studyFirstPostDateStruct":{"date":"2018-10-02","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-07-06","resultsFirstSubmitQcDate":"2022-09-09","resultsFirstPostDateStruct":{"date":"2022-10-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-05-24","lastUpdatePostDateStruct":{"date":"2024-06-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase II, open-label, multi-centre study to determine the safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) every 4 weeks \\[q4w\\] in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed following platinum-based sequential chemoradiation therapy (sCRT). This study will be conducted in Europe and North America.","detailedDescription":"This is a Phase II, open-label, multi-centre study to determine safety of a fixed dose of Durvalumab (MEDI4736) (1500 mg) monotherapy in participants with unresectable Stage III NSCLC who have not progressed following definitive, platinum-based sCRT. Approximately, 150 participants will be treated with the study drug in Europe and North America. Participants will be in complete response (CR), partial response (PR), or have stable disease (SD) following definitive, platinum-based sCRT, as assessed by the Investigator and further supported by the screening imaging radiological assessment. Participants must not have progressed following definitive, platinum-based sCRT; radiation therapy must be completed within 42 days prior to first Investigational product (IP) dose administration. Participants must have histologically- or cytologically-documented NSCLC and locally-advanced, unresectable Stage III disease. Participants will be treated with the study drug in 2 cohorts: approximately 100-120 participants in the World Health Organization/Eastern Cooperative Oncology Group Performance Status (WHO/ECOG PS) 0 to 1 Cohort and up to 30 participants in the WHO/ECOG PS 2 Cohort."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"keywords":["Stage III Non-Small Cell Lung Cancer","Durvalumab","IV infusion immunoglobulin G (IgG)","Antibody-dependent cellular cytotoxicity","Complement-dependent cytotoxicity","Monotherapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":117,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"WHO/ECOG PS 0 to 1 Cohort","type":"EXPERIMENTAL","description":"100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.","interventionNames":["Drug: Durvalumab"]},{"label":"WHO/ECOG PS 2 Cohort","type":"EXPERIMENTAL","description":"up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.","interventionNames":["Drug: Durvalumab"]}],"interventions":[{"type":"DRUG","name":"Durvalumab","description":"Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.","armGroupLabels":["WHO/ECOG PS 0 to 1 Cohort","WHO/ECOG PS 2 Cohort"],"otherNames":["MEDI4736"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)","description":"Safety and tolerability of Durvalumab as defined by Grade 3 and Grade 4 TRAEs following IV infusion administration was assessed.","timeFrame":"Up to 6 months"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of PFS. PFS was defined as the time from the first date of treatment until the date of objective disease progression based on Investigator's assessment according to RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression.","timeFrame":"From the first date of treatment until the date of objective disease progression or death (approximately upto 48 months)"},{"measure":"Percentage of Patients Progression-free at 12 Months","description":"The percentage of patients treated with Durvalumab who are progression-free was estimated. PFS12 according to RECIST 1.1 as assessed by the Investigator.","timeFrame":"From the first date of treatment until the date of objective disease progression or death (upto 12 months)"},{"measure":"Overall Survival (OS)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of OS were assessed. OS was defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.","timeFrame":"From the first date of treatment until death due to any cause (approximately upto 48 months)"},{"measure":"Percentage of Patients Alive","description":"Percentage of patients alive at 12 months, 24 months, and 36 months were estimated.","timeFrame":"From the first date of treatment until the date of objective disease progression or death (12 months, 24 months, and 36 months)"},{"measure":"Objective Response Rate (ORR)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of ORR were assessed. ORR (based on Investigator assessed response to treatment of complete response (CR) and partial response (PR) as per RECIST 1.1 criteria), together with the corresponding 95% CI, was reported for patients. Objective response is complete response (CR), or partial response (PR) confirmed by a follow-up visit at least 4 weeks after. Both visits contributing to response should have occurred before any further anti-cancer therapy, in order for the patient to be considered a responder. Responses that occurred after the start of subsequent anti-cancer therapy were not included in the numerator. Response excluded unconfirmed response. Participants with unconfirmed responses include those whose CR, or PR don't have a confirmed response. These responses occur at any time during the study, recur after anti-cancer therapy, and these participants were missing for a follow-up visit 4 weeks after.","timeFrame":"From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 52 weeks and every 12 weeks (q12w) ±1 week until disease progression (approximately upto 48 months)"},{"measure":"Duration of Response (DOR) From Onset of Response","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of DoR were assessed. DoR was defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression. If a patient did not progress following a response, then the patients' DoR was censored at the PFS censoring time.","timeFrame":"From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 52 weeks and q12w ±1 week until disease progression (approximately upto 48 months)"},{"measure":"Lung Cancer Mortality","description":"The efficacy of durvalumab (MEDI4736) treatment in terms of lung cancer mortality was assessed. Lung Cancer Mortality was defined as the time from the date of treatment start until death due to lung cancer. Any patient not known to have died due to lung cancer will be censored based on the last recorded date on which the patient was known to be alive or died due to reason other than lung cancer.","timeFrame":"From date of treatment start until death due to lung cancer (approximately upto 48 months)"},{"measure":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs)","description":"The safety and tolerability profile of Durvalumab(MEDI4736) treatment, including all AEs were assessed.","timeFrame":"Until the final visit (upto 48 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n2. Provision of signed and dated, written ICF prior to any mandatory study specific procedures, sampling, and analyses.\n3. Provision of signed and dated written genetic informed consent prior to collection of sample for genetic analysis (optional).\n4. 18 years or older at the time of signing the ICF.\n5. Histologically- or cytologically-documented NSCLC with locally-advanced, unresectable Stage III disease (according to the IASLC Staging Manual Version 8 \\[IASLC 2016\\]). Positron emission tomography (PET)/CT, MRI of the brain, and endobronchial ultrasound with biopsy are highly encouraged at diagnosis.\n6. Receipt of sCRT which must have been completed within 42 days prior to first IP dose administration in the study.\n\n   1. The platinum-based chemotherapy regimen must contain cisplatin or carboplatin and 1 of the following agents: etoposide, vinblastine, vinorelbine, a taxane (paclitaxel or docetaxel), or pemetrexed, according to the local standard of care (SoC) regimens. Platinum-based chemotherapy containing cisplatin or carboplatin and gemcitabine is permitted under certain conditions - refer to bullet point 6(b).\n   2. Patients must have received at least 2 cycles of platinum-based chemotherapy before radiation therapy. The interval between administration of the last dose of chemotherapy regimen and start of radiation therapy must be no more than 6 weeks. Consolidation chemotherapy after radiation is not permitted.\n\n   (i) If the patient's platinum-based chemotherapy contained gemcitabine, no overlap between chemotherapy and radiation therapy is permitted.\n\n   (ii) If the patient's platinum-based chemotherapy contained any of the agents listed in (a) other than gemcitabine, an overlap of 1 cycle of chemotherapy and radiation therapy is acceptable.\n\n   (c) Patients must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy). Sites are encouraged to adhere to mean organ radiation dosing as follows: (i) Mean lung dose \\<20 Gy and/or V20 \\<35%; (ii) Mean oesophagus \\<34 Gy; (iii) Heart V45 \\<35% or V30 \\<30%. Note: Sites should be aware of the recent RTOG 0617 Study data demonstrating that doses higher than 60 Gy may be associated with greater toxicity and worse efficacy.\n\n   (d) Patients with WHO/ECOG PS 2 or chronic lung disease (pulmonary emphysema or chronic obstructive pulmonary disease) must have received a V20 \\<25%.\n7. Patients must not have progressed following platinum-based sCRT, as per Investigator assessed RECIST 1.1 criteria. . In order to assess disease progression, the baseline imaging (CT/MRI) used for Screening purposes should be compared against the most recently performed scan that allows physician assessment as per RECIST 1.1 criteria. If an intermediate scan taken between chemotherapy and radiotherapy is available and that scan is suitable for physician assessment as per RECIST 1.1 criteria, then this scan should be used.\n\n   1. Patients with measurable disease and/or non-measurable and/or no evidence of disease (NED) assessed at baseline by CT/MRI will be entered in this study.\n   2. Prior irradiated lesions may be considered measurable and selected as TLs provided they fulfil the other criteria for measurability.\n8. Must have a life expectancy of at least 12 weeks at enrolment.\n9. WHO/ECOG PS ≤2.\n10. Adequate organ and marrow function at enrolment as defined below. These parameters should be achieved without augmentation by growth factors, transfusions, or infusions within 14 days of screening unless required for SoC:\n\n    1. Haemoglobin ≥9.0 g/dL;\n    2. Absolute neutrophil count \\>1.0 × 109/L;\n    3. Platelet count \\>75 × 109/L;\n    4. Serum bilirubin ≤1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician.\n    5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN.\n    6. Measured creatinine clearance \\>40 mL/min or calculated creatinine clearance \\>40 mL/min as determined by Cockcroft-Gault (using actual body weight) (Cockcroft and Gault 1976).\n\nMales:\n\nCreatinine clearance (mL/min) = Weight (kg) × (140 Age) 72 × serum creatinine (mg/dL)\n\nFemales:\n\nCreatinine clearance (mL/min) = Weight (kg) × (140 Age) × 0.85 72 × serum creatinine (mg/dL)\n\n11 Body weight \\>30 kg at enrolment and first IP dose administration. 12 Male or female. 13 Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n1. Women \\<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\nExclusion criteria:\n\n1. Patients with locally-advanced NSCLC whose disease has progressed following platinum based sCRT.\n2. Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumours.\n3. Mixed small-cell lung cancer and NSCLC histology.\n4. History of allogeneic organ transplantation.\n5. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[eg, colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n   1. Patients with vitiligo or alopecia.\n   2. Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.\n   3. Any chronic skin condition that does not require systemic therapy.\n   4. Patients without active disease in the last 5 years at enrolment may be included but only after consultation with the Study Physician.\n   5. Patients with celiac disease controlled by diet alone.\n6. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent.\n7. History of another primary malignancy except for:\n\n   1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence.\n   2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n   3. Adequately treated carcinoma in situ without evidence of disease.\n8. History of leptomeningeal carcinomatosis.\n9. History of active primary immunodeficiency.\n10. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive hepatitis B surface antigen \\[HbsAg\\] result), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies). Patients with a past or resolved hepatitis B virus (HBV) infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HbsAg) are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).\n11. Any unresolved toxicity of NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n\n    1. Patients with Grade ≥2 neuropathy or Grade ≥2 lymphopenia will be evaluated on a case-by-case basis after consultation with the Study Physician.\n    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab (MEDI4736) may be included only after consultation with the Study Physician.\n12. Known allergy or hypersensitivity to durvalumab (MEDI4736) or any of the IP excipients.\n13. Patients who have received cCRT for locally-advanced NSCLC, or who received sCRT with at least 2 concomitant CRT cycles. Prior surgical resection (ie, Stage I or II) is permitted.\n\n    Note: Patients whose platinum-based chemotherapy contained gemcitabine and who received sCRT with at least 1 concomitant CRT cycle are excluded from this study.\n14. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.\n\n    Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.\n15. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.\n\n    Note: Local surgery of isolated lesions for palliative intent is acceptable.\n16. Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines.\n17. Current or prior use of immunosuppressive medication within 14 days before the first dose of IP. The following are exceptions to this criterion:\n\n    1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection);\n    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent;\n    3. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).\n18. Previous IP assignment in the present study.\n19. Concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up period of an interventional study.\n20. Participation in another clinical study with an IP during the 4 weeks prior to the first IP dose administration.\n21. Prior randomisation or treatment in a previous durvalumab (MEDI4736) ± tremelimumab clinical study regardless of treatment arm assignment.\n22. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP.\n23. Judgment by the Investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements.\n24. Genetic research study (optional):\n\nExclusion criteria for participation in the optional (DNA) genetic research component of the study include:\n\n1. Previous allogeneic bone marrow transplant.\n2. Non-leukocyte-depleted whole blood transfusion in 120 days of genetic sample collection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Research Site","city":"Gainesville","state":"Georgia","zip":"30501","country":"United States","geoPoint":{"lat":34.29788,"lon":-83.82407}},{"facility":"Research Site","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Research Site","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Research Site","city":"Paris","zip":"75248","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Saint-Priest-en-Jarez","zip":"42270","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"facility":"Research Site","city":"Toulouse","zip":"31400","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Research Site","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Research Site","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Research Site","city":"Hamm","zip":"59063","country":"Germany","geoPoint":{"lat":51.68033,"lon":7.82089}},{"facility":"Research Site","city":"Hanover","zip":"30459","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Research Site","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Avellino","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"Research Site","city":"Meldola","zip":"47014","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"facility":"Research Site","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Monza","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"Research Site","city":"Parma","zip":"43126","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Research Site","city":"Roma","zip":"00152","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Guadalajara","zip":"19002","country":"Spain","geoPoint":{"lat":40.62862,"lon":-3.16185}},{"facility":"Research Site","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Valencia","zip":"46015","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Research Site","city":"Leeds","zip":"LS9 7TF","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}},{"facility":"Research Site","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Research Site","city":"Middlesbrough","zip":"TS4 3BW","country":"United Kingdom","geoPoint":{"lat":54.57623,"lon":-1.23483}},{"facility":"Research Site","city":"Nottingham","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"facility":"Research Site","city":"Sheffield","zip":"S10 2SJ","country":"United Kingdom","geoPoint":{"lat":53.38297,"lon":-1.4659}},{"facility":"Research Site","city":"Stoke-on-Trent","zip":"ST4 6QG","country":"United Kingdom","geoPoint":{"lat":53.00415,"lon":-2.18538}}]},"referencesModule":{"references":[{"pmid":"35961520","type":"DERIVED","citation":"Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sanchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub 2022 Aug 9."}],"seeAlsoLinks":[{"label":"CSP Redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4194C00006&amp;attachmentIdentifier=223d186d-4d3f-48ae-992c-86d35a9632c5&amp;fileName=AZ_D4194C00006-csp-v4_Redacted_PDF_A.pdf&amp;versionIdentifier="},{"label":"SAP Redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4194C00006&amp;attachmentIdentifier=03fb15bd-8baa-46db-808c-d332d239328f&amp;fileName=AZ_D4194C00006-sap-ed-5__Redacted_PDF_A.pdf&amp;versionIdentifier="},{"label":"CSR Synopsis Redacted","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4194C00006&amp;attachmentIdentifier=829673e0-d101-44cf-81e3-fb3a2f283905&amp;fileName=AZ_D4194C00006-study-synopsis_Redacted_PDF_A.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients who met all the inclusion and none of the exclusion criteria were included in the study. The screening period was from Day -28 to Day -1. The Study was scheduled from initiation of durvalumab up to a maximum of 24 months of treatment, 3 months of safety follow up and subsequent survival follow up as per CSP. Informed consent form was signed prior to screening procedures.","recruitmentDetails":"The study was conducted from 16 April 2019 to 21 April 2023 at 25 sites in the United States of America (USA), France, Germany, Italy, Spain, and the United Kingdom.","groups":[{"id":"FG000","title":"Durvalumab Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via Intravenous (IV) infusion every 4 weeks (q4w)."},{"id":"FG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The safety analysis set consisted of all patients who received at least one dose of (partial or in full) of study drug.","groups":[{"id":"BG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"BG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"117"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67.0","spread":"8.46"},{"groupId":"BG001","value":"65.0","spread":"12.00"},{"groupId":"BG002","value":"66.9","spread":"8.50"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"44"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"73"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"106"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"104"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"13"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)","description":"Safety and tolerability of Durvalumab as defined by Grade 3 and Grade 4 TRAEs following IV infusion administration was assessed.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 6 months","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"Any possibly related AEs of CTCAE Grade 3 or Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any possibly related AEs of Grade 3 or Grade 4 with onset date within 6 months of the first dose","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Any possibly related adverse events of CTCAE Grade 3 or Grade 4","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"6.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.50","ciUpperLimit":"12.24","estimateComment":"95% CI were based on the Clopper-Pearson method."},{"groupIds":["OG001"],"groupDescription":"Any possibly related adverse events of CTCAE Grade 3 or Grade 4","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.00","ciUpperLimit":"70.76","estimateComment":"95% CI were based on the Clopper-Pearson method."},{"groupIds":["OG002"],"groupDescription":"Any possibly related adverse events of CTCAE Grade 3 or Grade 4","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"6.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.44","ciUpperLimit":"11.94","estimateComment":"95% CI were based on the Clopper-Pearson method."},{"groupIds":["OG000"],"groupDescription":"Any possibly related AEs of Grade 3 or Grade 4 with onset date within 6 months of the first dose","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.44","ciUpperLimit":"9.94","estimateComment":"95% CI were based on the Clopper-Pearson method."},{"groupIds":["OG001"],"groupDescription":"Any possibly related AEs of Grade 3 or Grade 4 with onset date within 6 months of the first dose","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.00","ciUpperLimit":"70.76","estimateComment":"95% CI were based on the Clopper-Pearson method."},{"groupIds":["OG002"],"groupDescription":"Any possibly related AEs of Grade 3 or Grade 4 with onset date within 6 months of the first dose","nonInferiorityType":"OTHER","paramType":"Proportion (%)","paramValue":"4.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.40","ciUpperLimit":"9.69","estimateComment":"95% CI were based on the Clopper-Pearson method."}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of PFS. PFS was defined as the time from the first date of treatment until the date of objective disease progression based on Investigator's assessment according to RECIST 1.1 or death (by any cause in the absence of progression) regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the first date of treatment until the date of objective disease progression or death (approximately upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","lowerLimit":"7.36","upperLimit":"19.91"},{"groupId":"OG001","value":"3.7","lowerLimit":"1.81","upperLimit":"NA","comment":"Not calculated due to low number of events as well as low sample size."},{"groupId":"OG002","value":"13.1","lowerLimit":"7.36","upperLimit":"19.91"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Progression-free at 12 Months","description":"The percentage of patients treated with Durvalumab who are progression-free was estimated. PFS12 according to RECIST 1.1 as assessed by the Investigator.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of patient","timeFrame":"From the first date of treatment until the date of objective disease progression or death (upto 12 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","lowerLimit":"41.29","upperLimit":"60.02"},{"groupId":"OG001","value":"33.3","lowerLimit":"0.90","upperLimit":"77.41"},{"groupId":"OG002","value":"50.6","lowerLimit":"40.97","upperLimit":"59.45"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of OS were assessed. OS was defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the first date of treatment until death due to any cause (approximately upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","lowerLimit":"30.59","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG001","value":"12.3","lowerLimit":"4.96","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG002","value":"39.0","lowerLimit":"30.59","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Alive","description":"Percentage of patients alive at 12 months, 24 months, and 36 months were estimated.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of patient","timeFrame":"From the first date of treatment until the date of objective disease progression or death (12 months, 24 months, and 36 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"Survival at 12 months","categories":[{"measurements":[{"groupId":"OG000","value":"83.9","lowerLimit":"75.73","upperLimit":"89.57"},{"groupId":"OG001","value":"66.7","lowerLimit":"5.41","upperLimit":"94.52"},{"groupId":"OG002","value":"83.5","lowerLimit":"75.36","upperLimit":"89.15"}]}]},{"title":"Survival at 24 months","categories":[{"measurements":[{"groupId":"OG000","value":"68.2","lowerLimit":"58.54","upperLimit":"76.00"},{"groupId":"OG001","value":"33.3","lowerLimit":"0.90","upperLimit":"77.41"},{"groupId":"OG002","value":"67.2","lowerLimit":"57.73","upperLimit":"75.08"}]}]},{"title":"Survival at 36 months","categories":[{"measurements":[{"groupId":"OG000","value":"57.2","lowerLimit":"46.94","upperLimit":"66.20"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG002","value":"56.5","lowerLimit":"46.41","upperLimit":"65.46"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of ORR were assessed. ORR (based on Investigator assessed response to treatment of complete response (CR) and partial response (PR) as per RECIST 1.1 criteria), together with the corresponding 95% CI, was reported for patients. Objective response is complete response (CR), or partial response (PR) confirmed by a follow-up visit at least 4 weeks after. Both visits contributing to response should have occurred before any further anti-cancer therapy, in order for the patient to be considered a responder. Responses that occurred after the start of subsequent anti-cancer therapy were not included in the numerator. Response excluded unconfirmed response. Participants with unconfirmed responses include those whose CR, or PR don't have a confirmed response. These responses occur at any time during the study, recur after anti-cancer therapy, and these participants were missing for a follow-up visit 4 weeks after.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full). Patients without a post-baseline assessment were not included.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 52 weeks and every 12 weeks (q12w) ±1 week until disease progression (approximately upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"Number of patients with response","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"24"}]}]},{"title":"Number of patients with unconfirmed response","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) From Onset of Response","description":"The efficacy of Durvalumab (MEDI4736) treatment in terms of DoR were assessed. DoR was defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression. If a patient did not progress following a response, then the patients' DoR was censored at the PFS censoring time.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full). The patients with objective response were evaluated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Weeks","timeFrame":"From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 52 weeks and q12w ±1 week until disease progression (approximately upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."}]}]}]},{"type":"SECONDARY","title":"Lung Cancer Mortality","description":"The efficacy of durvalumab (MEDI4736) treatment in terms of lung cancer mortality was assessed. Lung Cancer Mortality was defined as the time from the date of treatment start until death due to lung cancer. Any patient not known to have died due to lung cancer will be censored based on the last recorded date on which the patient was known to be alive or died due to reason other than lung cancer.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full). Patients who had died due to causes related to non-small cell lung cancer were evaluated.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From date of treatment start until death due to lung cancer (approximately upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","lowerLimit":"36.50","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG001","value":"NA","lowerLimit":"4.96","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."},{"groupId":"OG002","value":"41.8","lowerLimit":"36.50","upperLimit":"NA","comment":"Not calculated due to insufficient number of events."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs)","description":"The safety and tolerability profile of Durvalumab(MEDI4736) treatment, including all AEs were assessed.","populationDescription":"The safety analysis set consisted of all patients who received at least one dose of IP (partial or in full). This include treatment emergent AEs only, ie. AEs occurred during screening period are NOT included.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Until the final visit (upto 48 months)","groups":[{"id":"OG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."},{"id":"OG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"117"}]}],"classes":[{"title":"Any AE","categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"111"}]}]},{"title":"Any AE possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"90"}]}]},{"title":"Any AE of CTCAE Grade 3 or Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"32"}]}]},{"title":"Any AE of CTCAE Grade 3 or Grade 4, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any AE with outcome of death","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}]}]},{"title":"Any AE with outcome of death, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Any SAE (including events with outcome of death)","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"32"}]}]},{"title":"Any SAE (including events with outcome of death), possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}]}]},{"title":"Any AE leading to discontinuation of treatment","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"32"}]}]},{"title":"Any AE leading to discontinuation of treatment, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}]}]},{"title":"Any AE leading to treatment interruption","categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"53"}]}]},{"title":"Any AE leading to treatment interruption, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"25"}]}]},{"title":"Any AESI or AEPI (including events with outcome of death)","categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"89"}]}]},{"title":"Any AESI or AEPI (including events with outcome of death), possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"75"}]}]},{"title":"Any imAE","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"50"}]}]},{"title":"Any imAE, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"45"}]}]},{"title":"Any imAE as assessed by Investigator","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"65"}]}]},{"title":"Any imAE as assessed by Investigator, possibly related to treatment","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"65"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2.5","timeFrame":"Upto 48 months","eventGroups":[{"id":"EG000","title":"Durvalumab ECOG PS 0 or 1","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w.","deathsNumAffected":50,"deathsNumAtRisk":114,"seriousNumAffected":32,"seriousNumAtRisk":114,"otherNumAffected":106,"otherNumAtRisk":114},{"id":"EG001","title":"Durvalumab ECOG PS 2","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w.","deathsNumAffected":2,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG002","title":"Durvalumab Total","description":"Patients received 1500 mg Durvalumab monotherapy via IV infusion q4w.","deathsNumAffected":52,"deathsNumAtRisk":117,"seriousNumAffected":32,"seriousNumAtRisk":117,"otherNumAffected":109,"otherNumAtRisk":117}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":117}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Covid-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pneumonia legionella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":117}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Tracheal stenosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":117}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]}],"otherEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":117}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":12,"numAffected":10,"numAtRisk":117}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":16,"numAffected":16,"numAtRisk":117}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":117}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":117}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":117}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":117}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":19,"numAffected":18,"numAtRisk":117}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":117}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":117}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":43,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":52,"numAffected":45,"numAtRisk":117}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":27,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":42,"numAffected":29,"numAtRisk":117}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":16,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":21,"numAffected":17,"numAtRisk":117}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":117}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":24,"numAffected":23,"numAtRisk":117}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":24,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":33,"numAffected":24,"numAtRisk":117}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":21,"numAffected":17,"numAtRisk":117}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":117}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":117}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":114},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":24,"numAffected":21,"numAtRisk":117}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":18,"numAffected":14,"numAtRisk":117}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":22,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":30,"numAffected":23,"numAtRisk":117}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":17,"numAffected":17,"numAtRisk":117}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":29,"numAtRisk":114},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3},{"groupId":"EG002","numEvents":42,"numAffected":31,"numAtRisk":117}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":24,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":35,"numAffected":24,"numAtRisk":117}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":22,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":25,"numAffected":22,"numAtRisk":117}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":15,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":19,"numAffected":16,"numAtRisk":117}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":117}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":13,"numAffected":8,"numAtRisk":117}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":117}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":117}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":117}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":117}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":117}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":117}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":117}]},{"term":"Oropharyngeal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":117}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Noninfective gingivitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":117}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":117}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":117}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":114},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":117}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":117}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":117}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":7,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":13,"numAffected":7,"numAtRisk":117}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":117}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":117}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 26.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":114},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":117}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object."},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca","email":"information.center@astrazeneca.com","phone":"1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-07-06","uploadDate":"2024-04-08T04:16","filename":"Prot_002.pdf","size":4298735},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-05-22","uploadDate":"2024-04-08T04:16","filename":"SAP_003.pdf","size":2373170}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2022-08-01","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"}]}},"hasResults":true}